Mediators of the effect of ertugliflozin on a composite kidney outcome in patients with type 2 diabetes and atherosclerotic cardiovascular disease: analyses from VERTIS CV
Event:
ESC Congress 2021 - The Digital Experience
Topic:
Renal Failure and Cardiovascular Disease
Session:
Cardiovascular Disease in Special Populations ePosters